Abstract
In this issue of Blood, Gavriatopoulou and colleagues report the mature results of the European Myeloma Network (EMN)-conducted phase 2 trial evaluating the activity of bortezomib, dexamethasone, and rituximab (BDR) in treatment-naïve patients with Waldenström macroglobulinemia (WM).1 An array of combination regimens has been studied in WM, and the ever-growing list of bidders contributes to the conundrum of choosing an appropriate regimen.2
Original language | English (US) |
---|---|
Pages (from-to) | 398-400 |
Number of pages | 3 |
Journal | Blood |
Volume | 129 |
Issue number | 4 |
DOIs |
|
State | Published - Jan 26 2017 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology